CanSino Biologics Inc.
Clinical trials sponsored by CanSino Biologics Inc., explained in plain language.
A vaccine company developing and manufacturing vaccines, including for COVID-19.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Could a Freeze-Dried vaccine shield all ages from hib? Results expected Oct 2026 (estimated)
- Could a Virus-Like particle vaccine outsmart polio? Results expected Oct 2026 (estimated)
- Tetanus immunity under the microscope: do antibodies hold up after 2.5 years? Results expected Nov 2026 (estimated)
- New 24-Strain pneumonia vaccine enters human trials Results expected Nov 2026 (estimated)
- New vaccine aims to shield infants from deadly pneumonia Results expected Feb 2027 (estimated) 🚀 Make-or-break
-
Could a Virus-Like particle vaccine outsmart polio?
Vaccine OngoingThis trial is testing an experimental vaccine made from virus-like particles (VLPs) that mimic polio viruses without causing disease. It aims to see if this vaccine is safe and triggers a strong immune response in healthy infants starting at 6 weeks old and toddlers aged 12-18 mo…
Phase 1/2 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
-
Could a Freeze-Dried vaccine shield all ages from hib?
Vaccine OngoingThis early-stage trial is testing a new freeze-dried version of the Haemophilus influenzae type b (Hib) vaccine to see if it is safe and triggers a protective immune response. The study includes healthy people aged 2 months, 6-11 months, 1-5 years, and 18-59 years, with younger g…
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 08, 2026 00:03 UTC
-
New vaccine aims to shield infants from deadly pneumonia
Vaccine OngoingThis study tests a new vaccine to protect babies against pneumococcal infections, which can cause pneumonia and meningitis. About 600 healthy infants in Thailand will receive either the new or a standard vaccine at 2, 4, and 12-15 months old. Researchers will check how well the v…
Phase 3 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Aug 07, 2026 00:00 UTC
-
New TB vaccine trial aims to shield millions
Vaccine OngoingThis early-stage study tests a new vaccine called Ad5-105K to see if it is safe and triggers an immune response against tuberculosis (TB). About 36 healthy adults aged 18 to 49 who have been exposed to TB bacteria (but have no active disease) will receive either the vaccine or a …
Phase 1 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:25 UTC
-
New vaccine study aims to shield toddlers from deadly meningitis
Vaccine OngoingThis study tests a vaccine designed to protect young children from four types of meningitis bacteria. Researchers gave the vaccine to 660 toddlers aged 6 to 23 months and will check their immune response over time. Some children will also receive a booster shot at age 3 to see if…
Phase 4 • Sponsor: CanSino Biologics Inc. • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC